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The purpose of this study is to evaluate the only available calcium p-aminosalicylate (Ca
PAS) commercial product, which is one of the most commonly prescribed non-surveillance
products from the Bureau of National Health Insurance (BNHI) database in Taiwan. An open-
randomized, balanced, two-way crossover study was designed to evaluate the relative
bioavailability (F) of a 500 mg Ca PAS F.C. tablet with a 500 mg Ca PAS suspension in 13
healthy individuals. Blood samples were collected according to a planned time schedule.
The plasma concentrations of PAS were measured by a validated liquid chromatography
coupledwith tandemmass spectrometry (LC/MS/MS)method. Pharmacokinetic parameters
of area under the plasma concentration-time curve from the time zero to the time of last
quantifiable concentration (AUC0et), area under the plasma concentration-time curve from
time zero to infinity (AUC0eN), maximum plasma concentration (Cmax), time to reach
measured maximum plasma concentration (Tmax), elimination half-life (T1/2), and mean
residence time (MRT) were determined by non-compartment methods. F was calculated by
[AUC0eN] of the test drug divided by [AUC0eN] of the reference drug. The mean geometric
ratios of pharmacokinetic parameters, including AUC0et, AUC0eN, and Cmax obtained were
0.873, 0.874, and 0.569, respectively. The 90% confidence intervals of ln (AUC0et), ln (AUC0eN),
and ln (Cmax) after being back natural log-transformed were (74.0e103.0%), (74.1e103.0%),
and (38.4e84.3%), respectively. The relative bioavailability of the Ca PAS tablet was 87.4%.
Copyright ª 2013, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC. Open access under CC BY-NC-ND license. 1. Introduction ensure the safety and efficacy of medicines. The BE study isThe Department of Health in Taiwan initiated the Guidance
for Bioavailability (BA)/Bioequivalence (BE) Studies in 1987, to, Taipei Medical Universi
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ministration, Taiwan. Publmandated for non-parenteral drugs with systemic effects and
proper distinction; these products are called surveillance
drugs [1e3]. BA/BE studies are not mandatory in Taiwan forty, Taiwan, ROC.
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products are named as non-surveillance drugs. With the
quality generic concept, evaluation of the BA/BE of commer-
cially available non-surveillance products is also encouraged.
Calcium p-aminosalicylate (Ca PAS) is an antimycobacterial
agent, which is bacteriostatic against Mycobacterium tubercu-
losis, by preventing the multiplication of bacteria, and is used
with other antituberculosis drugs (most often isoniazid) for
the treatment of all forms of active tuberculosis (TB), due to
susceptible strains of tubercle bacilli. The two major consid-
erations in the clinical pharmacology of Ca PAS are the prompt
productionof a toxic inactivemetabolite under acid conditions
and the short serum half-life within 1 hour for the free drug. It
is used as a second-line antimycobacterial agent and generally
reserved for patients withmultidrug-resistant TB (MDR-TB) or
patients intolerant to first-line drugs, including isoniazid,
rifampin, pyrazinamide, and ethambutol. It also inhibits the
onset of bacterial resistance to streptomycin and isoniazid
[4e7].
PAS is readily absorbed from the gastrointestinal tract, but
may cause irritation of the gastrointestinal mucosa, which
leads to increased peristalsis, and thus decreased absorption.
Because of this, the drug is best administered with food or an
antacid, such as aluminum hydroxide, which decreases irri-
tation but apparently has little effect on maximum plasma
concentration (Cmax). Patients with gastric resection were
found to have higher serum concentrations of PAS than
normal individuals [4]. PAS diffuses widely through body tis-
sues and fluids, although diffusion into the cerebrospinal fluid
(CSF) occurs only if themeninges are inflamed. In tissues, high
concentrations of PAS are achieved in lungs, kidneys, and the
liver. About 15% of the sodium salt and 50e70% of the free acid
is bound to plasma proteins. The volume of distribution was
1.43 (L/kg) in 12 healthy volunteers under fasting conditions,
after receiving 6 g PAS [8,9].
PAS is considered as an orphan drug, so relevant research
reports are few. It is one of the most prescribed non-
surveillance drugs from the Bureau of National Health In-
surance (BNHI) database and there is only one commercial
product available in Taiwan. Additionally, the original prod-
uct is no longer in the Taiwan market and no BA/BE study
has ever been done for this product. Therefore, it was chosen
as the candidate in this study to evaluate the relative
bioavailability of a 500 mg calcium p-aminosalicylate film
coating tablet.2. Materials and methods
2.1. Chemicals
The test product, a 500 mg F.C. Ca PAS tablet, and the raw
material for preparing the reference product, a Ca PAS sus-
pension, were obtained from PeiLi Pharm. Co, Taichung,
Taiwan. The average particle size of the active pharmaceutical
ingredient (API) of Ca PAS was around 23.2 mm, measured by
using a Coulter counter model: LS-230 (Beckman Coulter Inc.,
Fullerton, CA, USA). All other chemicals used were commer-
cially available and of analytical grade.2.2. Participants
Eligible participants were screened based on the inclusion and
exclusion criteria. They were required to refrain from any
prescription drug or herbal products within 14 days prior to
dosing. The study protocol was preapproved by the Institu-
tional Review Board (IRB) at the Ching Mai Hospital (Taipei,
Taiwan), and all participants gave written informed consent.
2.3. BA study
An open-label, randomized, balanced, two-sequence, two-
period, crossover design, with at least a 2-day washout period,
was carried out at clinical unit. During each treatment period,
participants would fast for at least 10 hours before investiga-
tional products were administered. They received 500 mg of
Ca PAS as one F.C. tablet or suspension with 240 mL water.
Participants continued to fast for 4 hours after dosing; drink-
ing water was not allowed during 1 hour before and 2 hours
after dosing.
For each treatment period, blood samples were collected
for pre-dose (0 hour) in the morning, and 0.167, 0.333, 0.667, 1,
1.5, 2, 3, 4, 6, 9, 12, and 24 hours after dosing using a hepa-
rinized syringe. Each collected blood sample was centrifuged,
and the supernatant plasma was placed in an appropriately
labeled tube, to be frozen at 20C until analysis.
2.4. Sample preparation and analysis
Each plasma sample (0.2 mL) was extracted with 0.5 mL
acetonitrile, followed by centrifugation at 3000 rpm for 10
minutes. Supernatant (100 mL) was then diluted with 500 mL
acetonitrile-acetic acid-water (15/0.1/85). Finally, an aliquot
(10 mL) was injected onto liquid chromatography coupled with
tandem mass spectrometry (LC/MS/MS).
The plasma concentrations of PAS were measured by a
validated liquid chromatography coupled with LC/MS/MS
method. The concentration of the standard curve ranged from
2 ng/mL to 500 ng/mL. For the plasma sample concentration
exceeding the standard curve concentration range, it would be
diluted and analyzed to fit the range. MS/MS analysis was
performed on an API 4000 triple quadrupole mass spectrom-
eter, which was operated in a turbo ion spray mode with
positive ion detection (PE Sciex, Concord, ON, Canada). The
samples were delivered into the Electron Spray Ion source
using the LC system (LC-10ADvp pump and SIL-HTA/HTC
autosampler, Shimadzu Corporation, Kyoto, Japan).
Separation was achieved on a Biosil ODS column
(4.6 mm  150 mm, 5 mm, Biotic Chemical Co., Ltd, Taipei,
Taiwan). A data processor was used with Analyst version 1.4
(PE Sciex).
2.5. Data treatment
Pharmacokinetic parameters including plasma elimination
rate constant (Kel), time to reach measured maximum plasma
concentration (Tmax), measured maximum plasma concen-
tration (Cmax), area under the plasma concentration-time
curve from the time zero to the time of last quantifiable con-
centration (AUC0et), area under the plasma concentration-
Table 1 e Precision and accuracy of QC samples.
Precision and accuracy of detecting PAS in human plasma
Within-run (n ¼ 6) Between-run (n ¼ 30)
PAS (ng/mL) 2 6 60 400 2 6 60 400
Mean 1.87 5.81 60.48 402.90 1.99 5.94 60.76 402.91
CV (%) 5.7 8.3 6.2 6.6 8.7 6.6 4.4 4.3
RE (%) 6.8 3.2 0.8 0.7 0.4 1.1 1.3 0.7
CV ¼ coefficient of variation; PAS ¼ p-aminosalicylate; RE ¼ relative error.
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plasma (first) moment concentration-time curve from time
zero to infinity (AUMC0eN), elimination half-life (T1/2), mean
residence time (MRT), and relative bioavailability (F) were
determined by non-compartmental methods. Pharmacoki-
netic parameters were described by means  SD. ANOVA was
performed to evaluate the impacts of sequence, subject
(within sequence), period and treatment effects on the raw or
log-transformed parameters of AUC0et, AUC0eN, Cmax, MRT,
and T1/2. Tmax comparisons were made by using the Wilcoxon
signed ranks test. Estimates of extent and rate of absorption
comparison in terms ofAUC0et,AUC0eN, and Cmax between the
test and reference drugs were calculated together with 90%
confidence intervals (CI), and tested for significance (p < 0.05).
In addition, F was calculated together also with 90% CI.3. Results
The validation of the standard curve covered a concentration
range from 2 ng/mL to 500 ng/mL. Human plasma was spiked
with quality control samples, for within-run and between-run
validation, at four concentrations, i.e., 2, 6, 60, and 400 ng/mL,
as shown in Table 1. The coefficient of variation and relative
error values are 4.3e8.7% and 1.1e1.3%, respectively, for
between-run validation, and 6.2e8.3% and 6.8e0.8%,
respectively, for within-run validations. These resultsTable 2 e Participant’s demographic data.
Participant no. Gender Age (y) Height
101 M 22 168.
102 M 27 176.
103 M 38 163.
104 M 23 173.
105 M 25 183.
106 M 22 172.
107 M 28 168.
108 M 25 177.
110 M 21 168.
111 M 27 168.
112 M 30 172.
113 M 24 170.
Mean 26.0 171.
SD 4.7 5.
R ¼ reference; T ¼ test; SD ¼ standard deviation.demonstrated that this analytical method can be used for the
BA study of PAS.
3.1. Pharmacokinetic data
Thirteen healthy Taiwanese male volunteers enrolled in the
study. The demographics of individuals who completed the
crossover study are listed in Table 2. Mean PAS plasma
concentration-time data of each sampling time obtained
after participants received the reference drug and test drug
are listed in Table 3. The plasma concentrations after 6 hours
are all below the lower limit of quantitation. Therefore, in
Fig. 1, the mean PAS plasma concentration-time profiles
presented, only covered up to 6 hours profile. Since the half-
life of PAS in this study is below 1 hour, sampling times of 6
hours were enough to describe the pharmacokinetics of PAS
in humans.
The mean plasma concentration-time profiles of PAS
after the participants received the reference and test drugs
are shown in Fig. 1. Pharmacokinetic parameters of PAS are
summarized in Table 4. The mean ratio and mean geo-
metric ratio of the reference drug and test drug of AUC0et
are 0.894 and 0.873, respectively, those of AUC0eN are 0.894
and 0.874, respectively, and those of Cmax are 0.615 and
0.569, respectively. The relative bioavailability value of Ca
PAS is 87.4 (%).
The results of ANOVA and 90% CI are listed in Table 5. As
shown in Table 5, the 90% CI of ln (AUC0et), ln (AUC0eN),(cm) Weight (Kg) Period I Period II
0 52.0 R T
0 70.0 T R
0 57.0 T R
0 68.0 R T
0 79.0 R T
0 70.0 T R
0 64.5 T R
0 65.0 R T
0 56.0 T R
0 67.0 R T
0 74.0 R T
0 56.0 R T
5 64.9
3 8.2
Table 3 e Mean plasma concentration-time data.
Time (h) Reference drug Test drug
Mean SD CV (%) Mean SD CV (%)
0 n. d. n. d. n. d. n. d. n. d. n. d.
0.167 4299.692 1727.986 40.2 474.634 1104.804 232.8
0.333 9251.769 4028.520 43.5 2609.908 3729.974 142.9
0.667 4895.846 1148.160 23.5 4329.154 3203.502 74.0
1 2700.385 671.505 24.9 3876.846 1980.192 51.1
1.5 990.615 382.051 38.6 2148.538 952.461 44.3
2 377.919 229.982 60.9 1149.692 786.696 68.4
3 53.398 49.899 93.4 150.781 126.196 83.7
4 9.712 9.477 97.6 19.299 13.991 72.5
6 0.627 1.209 192.8 1.308 1.573 120.3
9 n. d. n. d. n. d. n. d. n. d. n. d.
12 n. d. n. d. n. d. n. d. n. d. n. d.
24 n. d. n. d. n. d. n. d. n. d. n. d.
CV ¼ coefficient of variation; n.d. ¼ below quantitative limit; SD ¼ standard deviation.
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(74.0e103.0%), (74.1e103.0%) and (38.4e84.3%), respectively.
The 90% CI of F of the Ca PAS tablet are (74.6e102.3%) and the
mean is 87.4 %.
There were no adverse events during the study, and no
indications of clinical problems, such as blood pressure, heart
rate, or abnormal body temperature, which caused the with-
drawal of the participants. Therefore, we could infer that the
doses were tolerable and the trial was safe.0
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Fig. 1 e Mean plasma concentration-time profiles after the
participants have received the reference and the test drugs.4. Discussion
PAS inhibits the onset of bacterial resistance to streptomycin
and isoniazid. The mechanism of action was postulated to be
inhibition of folic acid synthesis (but without potentiation
with antifolic compounds) and/or inhibition of synthesis of
the cell wall component, mycobactin, thus reducing iron up-
take by Mycobacterium tuberculosis [4]. Since it has been pro-
vided for the patients in Taiwan, it is meaningful to evaluate
its BA.
From literature information [7], Tmax ranged from 2.09
hours to 6.64 hours and T1/2 of PAS ranged from 1.21 hours to
3.91 hours. In consideration of the last sampling time, the
schedule needed to be long enough to cover > three T1/2 after
reaching Cmax, and the blood sampling time up to 24 hours
should be sufficient for this requirement.
Based on the information from Martindale: The Complete
Drug Reference [4], after taking bymouth, PAS and its salts are
readily absorbed, and Cmax occurs after about 1 to 4 hours.
Both PAS and its sodium salt are readily absorbed from the
gastrointestinal tract, but absorption of the sodium salt is
faster and more complete than that of free acid. In addition, it
was demonstrated that the AUC was similar to all the salt
forms (Na, Ca, andK salts) butwas greatly different for the free
acid, for which it was postulated that dissolution of the rela-
tively insoluble acid was the rate-limiting factor [5]. However,
the report byWan et al [10], in which the bioavailability of PAS
and the Na, K, and Ca salts of PAS has been studied, indicated
that the absorption of PAS and its salts was essentially com-
plete and dissolution of PAS appears to be a rate-limiting
factor in its absorption. The type of administered salt
affected the rate of absorption. Although absorption of all four
compounds was complete, the areas under the plasma
concentration-time curve or the bioavailable drug were
dependent on the rate of absorption. The absorption of Na PAS
was faster than that for the other two salts.
Granule formulation has been developed and aerosol
formulation is developing [11,12] with an expectation of being
more effective to use. For lung delivery research [9], PAS was
formulated into large porous particles for direct delivery into
Table 4 e Pharmacokinetic parameters of orally administered 500 mg calcium p-aminosalicylate (Ca PAS) [n[ 13].
Parameters Reference drug Test drug Ratio (T/R)
Mean SD CV (%) Mean SD CV (%)
AUC0et (h*ng/mL) 6597.1 1660.2 25.2 5897.8 2087.3 35.3 0.916
AUC0ef (h  ng/mL) 6600.9 1661.8 25.2 5901.4 2086.6 35.4 0.916
Cmax (ng/mL) 9384.000 3815.436 40.7 5771.615 3435.791 59.5 0.731
Tmax (h) 0.392 0.124 31.7 0.962 0.420 43.7
MRT (h) 0.71 0.12 16.7 1.19 0.34 28.3
T1/2 (h) 0.38 0.08 20.2 0.40 0.09 23.6
AUC0et /AUC0ef 99.9 0.1 0.1 99.9 0.1 0.1
AUC0et ¼ area under the plasma concentration-time curve from the time zero to the time of last quantifiable concentration; AUC0ef ¼ area
under the plasma concentration-time curve from time zero to infinity; Cmax ¼maximum plasma concentration; CV ¼ coefficient of variation;
MRT¼mean residence time; SD¼ standard deviation; Tmax¼ time to reachmeasuredmaximum plasma concentration; T1/2¼ elimination half-
life.
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physical properties for deposition throughout the respiratory
tract. Systemic drug concentrations peaked at 15 minutes,
with a Cmax of 1171mg/mL. The results suggest that inhalation
delivery of PAS can potentially allow for a reduction in total
dose delivered, while providing higher local and similar peak
systemic drug concentrations as compared to those obtained
upon oral dosing.
From a study be Peloquin et al [9], Tmax was 4.43 hours
(ranging from 2.09 hours to 6.64 hours) in 12 healthy volun-
teers under fasting conditions, after receiving 6 g PAS gran-
ules. Cmax and AUC0eNwere 21.4 mg/mL (ranging from 11.4 mg/
mL to 79.3 mg/mL) and 140 mg  hour/mL (ranging from
20.8 mg  hour/mL to 255 mg  hour/mL), respectively. In
comparison with the reported data [7], the values of Cmax and
AUC0eN obtained for both the reference and the test drugs in
this study, after the dose was normalized to 500 mg, are
slightly smaller. The values of Tmax and T1/2 obtained for both
the reference and test drugs in this study are slightly faster
than the reported ones, but are consistent with the study ofTable 5 e Statistical analysis of calcium p-
aminosalicylate (Ca PAS).
Parameter Mean
geometric
ratio
90% CI p
Lower
bound
Upper
bound
Ln (AUC0-t )
(h*ng/ml)
0.873 74.0 103.0 0.158
Ln (AUC0-m)
(h*ng/ml)
0.874 74.1 103.0 0.158
Ln (Cmax)
(ng/ml)
0.569 38.4 84.3 0.026
Tmax (h) 1.689 143.2 194.5 0.001
MRT (h) 1.056 93.0 118.1 0.542
T1/2 (h) 2.453 e e 0.004
AUC0-t /AUC0-m 87.4 74.6 102.3 0.153
AUC0et¼ area under the plasma concentration-time curve from the
time zero to the time of last quantifiable concentration;
AUC0ef ¼ area under the plasma concentration-time curve from
time zero to infinity; Cmax ¼ maximum plasma concentration;
F ¼ relative bioavailability; MRT ¼ mean residence time;
Tmax ¼ time to reach measured maximum plasma concentration;
T1/2 ¼ elimination half-life.PAS by Wan et al [10]. Based on the study, the type of
administered salt affects the rate of absorption. AUC0eN or
bioavailable drug, are dependent on the rate of absorption [10].
The sodium salt, which could be easily dissolved to affect the
rate of absorption of PAS, was used [8]. Ca PAS is known to be
less toxic when compared to Na PAS. Because the Ca salt of
PAS dissolves more slowly, the rate of absorption is thus
slower. Since AUC0eN depends on the rate of absorption, Tmax
will be longer; the smaller Tmax is, the smaller is AUC.
Therefore, different doses, formulations, and salt forms
might affect pharmacokinetic profiles, causing the difference
in pharmacokinetic parameters obtained in this study (500mg
Ca PAS suspension and tablet) from those reported in the
literature (6 g PAS granules).5. Conclusion
From this study, the relative bioavailability of Ca PAS tablet
compared with suspension is 87.4%.
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